Speech-Language Pathologists in Middletown, MD Accepting Medicare
5 Speech-Language Pathologists found. Showing 1 - 5
 Kathryn Allen Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 403 Franklin St, Middletown, MD 21769 Phone: 240-566-0200 |
Mrs. Amanda Nicole Barnhard, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 17 W Main St, Middletown, MD 21769 Phone: 410-598-4336 |
Maureen Peltier, MA SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 201 E Green St, Middletown, MD 21769 Phone: 240-236-1100 |
Ms. Alexandra C Boo, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 303 Washington St, Middletown, MD 21769 Phone: 410-995-7555 |
Mrs. Lisa Rae Augustine, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8170 Hollow Road, Middletown, MD 21769 Phone: 301-371-3474 Fax: 301-371-6722 |
News Archive
Social influences can fuel weight loss
Is weight loss "contagious"? According to a new study published online in the journal Obesity, teammates in a team-based weight loss competition significantly influenced each other's weight loss, suggesting that shedding pounds can have a ripple effect.
AvidBiotics granted U.S. and European patents concerning its DGR technology platform
AvidBiotics Corp. announced the issuance of foundational patents encompassing a completely novel mechanism for generating massive diversity within precisely targeted sites of protein-encoding DNA sequences. The technology platform is referred to as Diversity Generating Retroelements (DGR) and patents were issued in both the United States (#7,585,957) and in Europe (#1,173,995). UCLA and AvidBiotics Corp are co-assignees of the patents, and AvidBiotics holds exclusive, worldwide rights to the patents from UCLA.
Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout
TWi Biotechnology Inc. today announced interim results from the ongoing Phase 2 proof of concept clinical study evaluating AC-201 CR as an oral uricosuric and anti-inflammatory agent for the treatment of hyperuricemia and prevention of gout flares combining with febuxostat, a xanthine oxidase inhibitor.
New poll show Americans oppose cuts to Medicare, Medicaid
Though concerns continue to mount regarding the nation's fiscal problems, a new poll finds most Americans would prefer to keep Medicare just as it is.
Scientists explore household bacteria to produce top-quality cheese
The Norwegian dairy company TINE is now planning an in-depth study that will find out whether household bacteria can be used for their own sake.
› Verified 4 days ago
Speech-Language Pathologists
Physical Therapists
Optometrists
Occupational Therapists